3B Future Health Fund

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

Sibylla Biotech S.R.L. is an Italian company focused on advancing rational drug design in the pharmaceutical sector. The company specializes in the research, development, and production of innovative therapeutic solutions, particularly through the creation of small molecule folding interfering degraders (FIDs) that target a variety of therapeutic areas. Additionally, Sibylla Biotech provides consultancy services in biotechnology and drug development. The company utilizes patent-based software that applies advanced algorithms and drug design protocols, enabling efficient drug discovery by optimizing reaction paths and streamlining data processes. This approach aims to enhance the rationalization of drug discovery efforts, ultimately contributing to the treatment of challenging medical conditions.

Roca Therapeutics is engaged in the research and development of innovative treatments for severe, life-threatening diseases, particularly those associated with hypervascularization and the immunosuppressive effects of M2 macrophages. The company employs a biotechnology platform aimed at creating novel cancer therapies that target critical factors in tumor development, inflammation, and tumor cell proliferation. By focusing on these mechanisms, Roca Therapeutics seeks to provide patients with new therapeutic options and improve outcomes for those suffering from rare forms of cancer.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

GenEp, Inc. is a pre-clinical stage biotechnology company focused on developing therapies for rare genetic epilepsies and other treatment-resistant epilepsies. The company utilizes its intellectual property to create selective compounds that modulate sodium and other ion channels, addressing mutations that contribute to these conditions. By targeting the specific genetic mutations responsible for treatment resistance, GenEp aims to enable medical professionals to provide more effective therapeutic options for patients suffering from these challenging disorders.

GreenBone specializes in the development of innovative bone implants derived from bamboo wood, designed to address severe fractures and conditions that lead to significant bone loss, such as trauma and tumors. The company’s technology transforms bamboo into hydroxyapatite, a widely utilized biomaterial that serves as a bone graft scaffold. These biomimetic, reabsorbable implants possess the necessary weight-bearing and bone regeneration properties to effectively treat non-union fractures. Founded by a research group from ISTEC-CNR of Faenza, GreenBone aims to provide bio-inspired solutions that can significantly improve patient outcomes in orthopedic care.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Gain Therapeutics is a biotechnology company focused on developing pharmacological chaperones to address rare metabolic disorders and other diseases. Established in 2017 and headquartered in Bethesda, Maryland, the company is dedicated to innovating drug therapies, particularly for lysosomal storage disorders, central nervous system disorders, and metabolic conditions. Its clinical-stage candidate, GT-02287, targets GBA1 Parkinson's disease. Gain Therapeutics employs a computational platform called Magellan to discover novel allosteric binding sites on disease-related proteins, enabling the identification of proprietary small molecules that can enhance protein function and address the root causes of various diseases. By developing targeted therapies, the company aims to meet significant unmet medical needs, particularly in pediatric genetic disorders.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

GreenBone specializes in the development of innovative bone implants derived from bamboo wood, designed to address severe fractures and conditions that lead to significant bone loss, such as trauma and tumors. The company’s technology transforms bamboo into hydroxyapatite, a widely utilized biomaterial that serves as a bone graft scaffold. These biomimetic, reabsorbable implants possess the necessary weight-bearing and bone regeneration properties to effectively treat non-union fractures. Founded by a research group from ISTEC-CNR of Faenza, GreenBone aims to provide bio-inspired solutions that can significantly improve patient outcomes in orthopedic care.

QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

QuantuMDx Group Limited is a medical devices company that specializes in developing portable and affordable diagnostic tools for use in various healthcare settings, including clinics, pharmacies, hospitals, and laboratories. Founded in 2008 and based in Newcastle upon Tyne, United Kingdom, with subsidiaries in the United States and Singapore, the company offers products such as Q-POC, a battery-operated molecular diagnostic device that delivers sample-to-result testing in 10 to 30 minutes for various biological samples. QuantuMDx's diagnostic solutions are applicable in areas such as warfarin prediction, HPV diagnostics, drug susceptibility testing, and sexually transmitted infection panel testing. Additionally, the company has developed the Internet of Life, a real-time global pathogen monitoring system, aimed at enhancing disease detection and management. QuantuMDx's innovations support personalized medicine, making advanced diagnostics accessible in both developed and developing nations.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.